CBD Research

To understand what’s in our high CBD oil and salves, it’s helpful to understand two terms. They’re pretty scary-looking, but what they mean is simple:

  1. The first is “CBD” or ”Cannabidiol” (pron. kuh-NAB-uh-DYE-all). This is a non-psychoactive compound in the hemp plant. Researchers are intrigued by CBD’s effects on cancer, chronic pain, neuro-degenerative conditions, psychological disorders, and other maladies.
  2. The second is “THC” (Delta-9-tetrahydrocannabinol). This is the controlled substance that humans use to get high. There is essentially no THC in our products. Tests in a state-of-the-art lab certify that there is less than 1%. That’s well below what a person can feel.

Let us emphasize, again, that we cannot make medical claims for CBD. We can only say, again, that medical scientists are actively pursuing research into the compound today.
We cite some of that CBD research below.

British Journal of Clinical Pharmacology
“Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?”
2013 Feb;75(2):323-33. doi: 10.1111/j.1365-2125.2012.04341.x.
Fernández-Ruiz J1, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J.“Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous disorders exerted through molecular mechanisms that are yet to be completely identified. CBD acts in some experimental models as an anti-inflammatory, anticonvulsant, anti-oxidant, anti-emetic, anxiolytic and antipsychotic agent, and is therefore a potential medicine for the treatment of neuroinflammation, epilepsy, oxidative injury, vomiting and nausea, anxiety and schizophrenia, respectively. The neuroprotective potential of CBD, based on the combination of its anti-inflammatory and anti-oxidant properties, is of particular interest and is presently under intense preclinical research in numerous neurodegenerative disorders. In fact, CBD combined with Δ(9)-tetrahydrocannabinol is already under clinical evaluation in patients with Huntington’s disease to determine its potential as a disease-modifying therapy.”
http://www.ncbi.nlm.nih.gov/pubmed/22625422

National Institutes of Health
National Cancer Institute
“Cannabis and Cannabinoids: Overview” 17 December 2014
http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional/page1An excellent overview of the present state of research. It covers:

  1. The use of cannabinoids in “complementary and alternative medicine”;
  2. The two major compounds in the hemp plant, THC (the controlled intoxicant) and cannabidiol (CBD, the non-psychoactive compound);
  3. The changing legal status of marijuana;
  4. The use of specific cannabinoids as drugs approved by the FDA; and
  5. Remarks on cannabinoids’ potential benefits in the treatment of cancer-related side effects.
“An in vitro study of the effect of CBD on programmed cell death in breast cancer cell lines found that CBD induced programmed cell death, independent of the CB1, CB2, or vanilloid receptors. CBD inhibited the survival of both estrogen receptor–positive and estrogen receptor–negative breast cancer cell lines, inducing apoptosis in a concentration-dependent manner while having little effect on nontumorigenic mammary cells.”“CBD has also been demonstrated to exert a chemopreventive effect in a mouse model of colon cancer.[21] . . . Animals treated with azoxymethane and CBD concurrently were protected from developing premalignant and malignant lesions. In in vitro experiments involving colorectal cancer cell lines, the investigators found that CBD protected DNA from oxidative damage, increased endocannabinoid levels, and reduced cell proliferation.”

National Institutes of Health
Epilepsy Behavior
“Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.”
Epilepsy Behav. 2013 Dec;29(3):574-7. doi: 10.1016/j.yebeh.2013.08.037.
http://www.ncbi.nlm.nih.gov/pubmed/24237632British Journal of Psychology
“Therapeutic aspects of cannabis and cannabinoids”
DOI: 10.1192/bjp.178.2.107 Published 1 February 2001
http://bjp.rcpsych.org/content/178/2/107.full

Institute of Medicine
“Marijuana and Medicine: Assessing the Science Base”
National Academy Press, Washington D.C.

“Defined substances, such as purified cannabinoid compounds, are preferable to plant products, which are of variable and uncertain composition. Use of defined cannabinoids permits a more precise evaluation of their effects, whether in combination or alone.” Page 3, paragraph 3.

Nature
“Cannabidiol [CBD] enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia”
Citation: Translational Psychiatry (2012) 2, e94; doi:10.1038/tp.2012.15
Published online 20 March 2012
http://www.nature.com/tp/journal/v2/n3/full/tp201215a.html“In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol [CBD] vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. Either treatment was safe and led to significant clinical improvement, but cannabidiol displayed a markedly superior side-effect profile. Moreover, cannabidiol treatment was accompanied by a significant increase in serum anandamide levels, which was significantly associated with clinical improvement.”

British Journal of Pharmacology
2013, Oct 4.
Ward SJ, McAllister SD, Neelakantan H, Walker EA.
“Cannabidiol [CBD] inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy.”Breast Cancer Research Treatment
“Pathways mediating the effects of cannabidiol [CBD] on the reduction of breast cancer cell proliferation, invasion, and metastasis.”
2011 Aug;129(1):37-47.
McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C, Liu Y, Debs RJ, Moore DH, Desprez PY.

CBD Law

The U.S. Ninth Circuit Court of Appeals has already issued a unanimous decision on the legality of non-psychoactive hemp products (DEA v. Hemp Industries Association, 2004). The ruling makes two essential points:

  1. “Non-psychoactive hemp is not included in Schedule I,” i.e., the Federal list of controlled substances;
  2. The DEA’s treatment of trace amounts of THC as dangerous drugs “contravenes the unambiguously expressed intent of Congress in the Controlled Substances Act (CSA), and cannot be upheld.”

The background: A few years ago, DEA tried to add any product with even trace amounts of THC to the DEA’s “Schedule 1,” a listing of illegal psychoactive compounds. This action would have made anything made of hemp—including oil, salves, furniture, clothing, rope, seeds, and other products—illegal.
The Hemp Industries Association (HIA) took DEA to court, saying that this interpretation had no basis in law. On 6 February 2004, the court agreed with HIA, issuing the unanimous decision cited above. The DEA did not appeal.
Splash Living’s High-CBD Oil and High-CBD Salve are derived from the “non-psychoactive hemp” that the Ninth Circuit says is not a controlled substance. It contains almost no THC. You have as much chance of getting high on our hemp oil as you do from getting addicted to heroin by eating poppy-seed bagels.